Emergent BioSolutions at H.C. Wainwright conference: debt falls

On Monday, 14 September 2026, Emergent BioSolutions (EBS) showcased a more streamlined and financially stronger company at the H.C. Wainwright 28th Annual Global Investment Conference. Chief Executive Joe Papa and Chief Financial Officer Rich Lindahl highlighted revenue and profit growth, while acknowledging challenges in their naloxone product line and an evolving competitive landscape. The company is relying on its biodefense portfolio, international market expansion, and manufacturing strengths to drive future growth.

Revenue for the year to date stood at $390 million, a $27 million increase from the same period in the previous year. Adjusted EBITDA reached $132 million, up $20 million year-over-year, with the adjusted EBITDA margin expanding by 3 percentage points. Operating expenses fell by $13 million despite revenue growth.

Second-quarter medical countermeasures revenue was reported at $168 million, the highest in the segment since 2020, though NARCAN still holds about 50% market share due to pricing pressure from four generic competitors. The company has been expanding its presence beyond the U.S. government market, with about 20% of medical countermeasures revenue now coming from international customers, particularly in Europe, the Middle East, and Asia.

Debt has been significantly reduced, dropping from approximately $800 million to $515 million. The company refinanced a $250 million term loan to $150 million and extended maturity to 2031, repurchased $75 million of unsecured bonds. Net leverage is now about 2.0 times. Cash generation is supporting this debt reduction plan, as described by Papa as a key part of the turnaround effort.

The naloxone business remains a significant growth engine, but faces competition from four generic rivals. Efforts to offset this pressure include $40 million in expense reductions, including lab closures, office space sales, and warehouse lease exits.